NYSEAMERICAN:XTNT

Xtant Medical (XTNT) Stock Price, News & Analysis

$0.89
-0.02 (-2.20%)
(As of 04/24/2024 ET)
Today's Range
$0.89
$0.94
50-Day Range
N/A
52-Week Range
$0.60
$1.45
Volume
33,936 shs
Average Volume
144,778 shs
Market Capitalization
$115.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.60

Xtant Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
79.8% Upside
$1.60 Price Target
Short Interest
Healthy
0.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.10 out of 5 stars

XTNT stock logo

About Xtant Medical Stock (NYSEAMERICAN:XTNT)

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.

XTNT Stock Price History

XTNT Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Q4 2023 Xtant Medical Holdings Inc Earnings Call
Xtant Medical Holdings, Inc. (XTNT)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
BTIG Keeps Their Buy Rating on Xtant Medical Holdings (XTNT)
Xtant Medical Holdings Inc XTNT
Q3 2023 Xtant Medical Holdings Inc Earnings Call
See More Headlines
Receive XTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2024
Today
4/25/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:XTNT
Employees
207
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.60
High Stock Price Target
$2.00
Low Stock Price Target
$1.20
Potential Upside/Downside
+79.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$660,000.00
Pretax Margin
-1.14%

Debt

Sales & Book Value

Annual Sales
$91.30 million
Cash Flow
$0.03 per share
Book Value
$0.39 per share

Miscellaneous

Free Float
117,456,000
Market Cap
$115.90 million
Optionable
Not Optionable
Beta
0.22
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Sean E. Browne (Age 58)
    President, CEO & Director
    Comp: $1.29M
  • Mr. Mark A. Schallenberger (Age 38)
    Chief Operations Officer
    Comp: $778.42k
  • Mr. Kevin D. Brandt (Age 58)
    Senior VP & Chief Commercial Officer
    Comp: $658.03k
  • Mr. Scott C. Neils (Age 40)
    Chief Financial Officer
    Comp: $517.86k
  • Ms. Catherine Lundy
    Vice President of Human Resources

XTNT Stock Analysis - Frequently Asked Questions

Should I buy or sell Xtant Medical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XTNT shares.
View XTNT analyst ratings
or view top-rated stocks.

What is Xtant Medical's stock price target for 2024?

2 Wall Street research analysts have issued 1 year price targets for Xtant Medical's stock. Their XTNT share price targets range from $1.20 to $2.00. On average, they predict the company's stock price to reach $1.60 in the next twelve months. This suggests a possible upside of 79.8% from the stock's current price.
View analysts price targets for XTNT
or view top-rated stocks among Wall Street analysts.

Are investors shorting Xtant Medical?

Xtant Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 280,600 shares, an increase of 45.8% from the March 15th total of 192,500 shares. Based on an average daily volume of 145,100 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.6% of the company's shares are sold short.
View Xtant Medical's Short Interest
.

When is Xtant Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our XTNT earnings forecast
.

How were Xtant Medical's earnings last quarter?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) released its quarterly earnings results on Monday, April, 1st. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The medical device company had revenue of $28.11 million for the quarter. Xtant Medical had a trailing twelve-month return on equity of 1.56% and a net margin of 0.72%.

When did Xtant Medical's stock split?

Shares of Xtant Medical reverse split on the morning of Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What guidance has Xtant Medical issued on next quarter's earnings?

Xtant Medical issued an update on its FY 2024 earnings guidance on Monday, April, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $112.0 million-$116.0 million, compared to the consensus revenue estimate of $115.9 million.

What other stocks do shareholders of Xtant Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xtant Medical investors own include Aurinia Pharmaceuticals (AUPH), LadRx (CYTR), Heat Biologics (HTBX), Neovasc (NVCN), Rexahn Pharmaceuticals (REXN), Biopharmx (BPMX), Adamis Pharmaceuticals (ADMP), Lipocine (LPCN) and Synergy Pharmaceuticals (SGYP).

How do I buy shares of Xtant Medical?

Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:XTNT) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners